As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator»s biologic products. But scientific challenges remain due to the complexity of both the manuf
¡Compre este libro electrónico y obtenga 1 más GRATIS!
Formato PDF ● Páginas 444 ● ISBN 9781466579705 ● Editorial CRC Press ● Publicado 2013 ● Descargable 6 veces ● Divisa EUR ● ID 2715426 ● Protección de copia Adobe DRM
Requiere lector de ebook con capacidad DRM